【摘要】 目的 探讨2021年中关村地区高血压患者基因多态性和当年降压药使用情况，为临床合理用药提供依据。方法 通过医院信息系统，对2021年中关村医院全年进行高血压基因检测人群的相关基因情况进行统计，并对同年降压药使用情况进行分类汇总，分析人群敏感基因与降压药使用情况的关系，同时对当年高血压用药情况进行分析。结果 2021年中关村地区的高血压患者，携带TT型基因的人群占100%，同时钙通道阻滞剂（CCB）类降压药使用金额和用药频度（DDDs）最高，CCB中氨氯地平使用量和金额排名第一。结论 临床应根据基因多态性来选择降压药，需加强对基因检测的宣传，使患者和医师尽快认识到在进行降压治疗前进行基因检测的重要性。更多还原

【Abstract】 Objective To explore the gene polymorphisms of hypertensive patients in Zhongguancun area in 2021 and the use of antihypertensive drugs, so as to provide a basis for rational drug use. Methods Through the hospital information system, statistics on the related genes of the population with hypertension gene testing in Zhongguancun Hospital in 2021 were carried out, and the use of antihypertensive drugs in the same year was classified and summarized, and the relationship between sensitive genes and the use of antihypertensive drugs in the population was analyzed. At the same time, the drug use of hypertension in the year was analyzed. Results In 2021, 100% of hypertension patients in Zhongguancun area will carry TT gene, and the amount and frequency of use(DDDs) of calcium channel blockers(CCB) antihypertensive drugs will be the highest. The amount and amount of use of amlodipine in CCB will rank first. Conclusion Clinical selection of antihypertensive drugs should be based on genetic polymorphism, and promotion of genetic testing should be strengthened to make patients and physicians aware of the importance of conducting genetic testing before undergoing antihypertensive treatment as soon as possible.更多还原